Merck's Zetia cuts heart attack, stroke risk in long-awaited study

November 17, 2014 4:39 PM

13 0

CHICAGO (Reuters) - After years of uncertainty, a nearly decade-long study showed that Merck & Co's cholesterol drug Zetia significantly lowered the risk of heart attacks and strokes in high-risk heart patients when used with a highly effective statin.

The data, released Monday, proves that Zetia - widely used for a dozen years due to its ability to lower "bad" LDL cholesterol levels - provides important protection to some patients, and supports a theory that bringing LDL down to very low levels adds further benefit.

Read more

To category page